Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial.
It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial.
In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial.
Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines.
It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 25 | -0.44 Decreased by -76.00% | -0.49 Increased by +10.20% |
| Feb 11, 25 | -0.46 Decreased by -109.09% | -0.52 Increased by +11.54% |
| Nov 7, 24 | -0.42 Increased by +36.36% | -0.39 Decreased by -7.69% |
| Aug 13, 24 | -0.35 Increased by +62.77% | -0.40 Increased by +12.50% |
| Jun 11, 24 | -0.25 Increased by +85.71% | -0.36 Increased by +30.56% |
| Feb 13, 24 | -0.22 Decreased by -340.00% | -0.30 Increased by +26.67% |
| Nov 9, 23 | -0.66 Decreased by -725.00% | -0.68 Increased by +2.94% |
| Aug 10, 23 | -0.94 Decreased by -840.00% | -0.04 Decreased by -2.27 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | -15.00 K Decreased by -107.60% | -13.63 M Decreased by -43.20% | Increased by +90.90 K% Increased by +1.98 K% |
| Dec 31, 24 | 234.00 K Decreased by -43.12% | -14.09 M Decreased by -121.88% | Decreased by -6.02 K% Decreased by -290.09% |
| Sep 30, 24 | 183.00 K Decreased by -34.17% | -12.96 M Decreased by -96.74% | Decreased by -7.08 K% Decreased by -198.87% |
| Jun 30, 24 | 84.00 K Decreased by -52.54% | -10.73 M Decreased by -55.48% | Decreased by -12.78 K% Decreased by -227.63% |
| Mar 31, 24 | 197.30 K Increased by +12.36% | -9.52 M Increased by +22.13% | Decreased by -4.83 K% Increased by +30.69% |
| Dec 31, 23 | 411.40 K Increased by +129.06% | -6.35 M Increased by +34.95% | Decreased by -1.54 K% Increased by +71.60% |
| Sep 30, 23 | 278.00 K Increased by +131.15% | -6.59 M Increased by +62.30% | Decreased by -2.37 K% Decreased by -221.02% |
| Jun 30, 23 | 177.00 K Decreased by -42.92% | -6.90 M Increased by +65.09% | Decreased by -3.90 K% Increased by +38.85% |